- Home
- EXLS vs ROIV Comparison
EXLS vs ROIV Comparison
Compare EXLS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXLS
- ROIV
- Stock Information
- Founded
- EXLS 1999
- ROIV 2014
- Country
- EXLS United States
- ROIV United Kingdom
- Employees
- EXLS N/A
- ROIV N/A
- Industry
- EXLS Business Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- EXLS Consumer Discretionary
- ROIV Health Care
- Exchange
- EXLS Nasdaq
- ROIV Nasdaq
- Market Cap
- EXLS 7.0B
- ROIV 8.4B
- IPO Year
- EXLS 2006
- ROIV N/A
- Fundamental
- Price
- EXLS $46.07
- ROIV $10.79
- Analyst Decision
- EXLS Strong Buy
- ROIV Buy
- Analyst Count
- EXLS 7
- ROIV 4
- Target Price
- EXLS $50.29
- ROIV $17.50
- AVG Volume (30 Days)
- EXLS 1.6M
- ROIV 5.9M
- Earning Date
- EXLS 04-29-2025
- ROIV 05-29-2025
- Dividend Yield
- EXLS N/A
- ROIV N/A
- EPS Growth
- EXLS 21.21
- ROIV N/A
- EPS
- EXLS 1.32
- ROIV N/A
- Revenue
- EXLS $1,902,884,000.00
- ROIV $122,585,000.00
- Revenue This Year
- EXLS $14.18
- ROIV N/A
- Revenue Next Year
- EXLS $11.43
- ROIV N/A
- P/E Ratio
- EXLS $34.88
- ROIV N/A
- Revenue Growth
- EXLS 14.18
- ROIV 140.04
- 52 Week Low
- EXLS $28.59
- ROIV $8.73
- 52 Week High
- EXLS $52.43
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- EXLS 50.90
- ROIV 50.06
- Support Level
- EXLS $45.31
- ROIV $10.58
- Resistance Level
- EXLS $48.16
- ROIV $11.77
- Average True Range (ATR)
- EXLS 1.50
- ROIV 0.34
- MACD
- EXLS 0.05
- ROIV -0.07
- Stochastic Oscillator
- EXLS 45.82
- ROIV 17.65
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.